MDWD MediWound Ltd.

5.06
-0.13  -2%
Previous Close 5.19
Open 5.58
Price To Book -72.29
Market Cap 137527643
Shares 27,178,839
Volume 144,847
Short Ratio
Av. Daily Volume 414,051

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Pivotal trial to be initiated 1H 2019.
EscharEx
Chronic and other hard-to-heal wounds
Phase 3 data released January 22, 2019 - endpoints met.
NexoBrid
Severe burns

Latest News

  1. MediWound: 4Q Earnings Snapshot
  2. MediWound Reports Fourth Quarter and Fiscal Year 2018 Financial Results
  3. MediWound to Host Fourth Quarter & Fiscal 2018 Financial Results Conference Call on March 25 at 8:30 a.m. Eastern Time
  4. MediWound Announces Executive Leadership Changes
  5. Earnings Preview: MediWound (MDWD) Q4 Earnings Expected to Decline
  6. Do Institutions Own MediWound Ltd. (NASDAQ:MDWD) Shares?
  7. 4 Healthcare Stocks Looking to Set the Pace on Tuesday (1/22/19)
  8. MediWound Announces Positive Top-Line Results from Its Pivotal Phase 3 Study (DETECT) in NexoBrid® for Eschar Removal of Severe Thermal Burns
  9. MediWound’s Late Stage Clinical Products Review, Analysts Review and Target
  10. Edited Transcript of MDWD earnings conference call or presentation 13-Nov-18 1:30pm GMT
  11. Small Drug Stocks Near-Term Outlook Positive, Despite Headwinds
  12. MediWound Ltd (NASDAQ:MDWD): Time For A Financial Health Check
  13. MediWound (MDWD) Reports Q3 Loss, Lags Revenue Estimates
  14. MediWound Reports Third Quarter 2018 Financial Results
  15. Analysts Estimate MediWound (MDWD) to Report a Decline in Earnings: What to Look Out for
  16. MediWound to Host Third Quarter 2018 Financial Results Conference Call on November 13 at 8:30 a.m. Eastern Time
  17. MediWound (MDWD) Reports Q2 Loss, Tops Revenue Estimates